[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Viktoras Rudzianskas\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100623031","precision-medicine-mri-guided-stereotactic-ablative-radiotherapy-mri-sabr-for-early-stage-glottic-laryngeal-cancer-100623031",false,"NCT07391345","Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer","A Prospective, Randomized, Three-Arm, Open-Label Clinical Trial Comparing Transoral CO₂ Laser Microsurgery, Volumetric Modulated Arc Therapy (VMAT), and MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) in the Treatment of Early-Stage Glottic Laryngeal Cancer","SMART - 1_1","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed squamous cell carcinoma of the glottic larynx, including verrucous carcinoma.\n* Stage T1-T2N0 (8th TNM edition).\n* ECOG performance status 0-2.\n* Able to understand Lithuanian and complete questionnaires.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* AJCC stage III-IV laryngeal cancer.\n* Prior radiotherapy for head and neck cancer.\n* Pregnancy or breastfeeding.\n* Contraindications for radiotherapy or inability to follow-up.\n* Presence of another active malignancy.\n* Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, clinically significant arrhythmia) or any condition that would preclude radiotherapy or adequate follow-up per investigator judgment.","ALL","18 Years",{"count":20,"type":21},105,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized phase III trial will compare the outcomes of three treatment modalities for early-stage glottic laryngeal cancer (T1-T2N0): transoral CO₂ laser microsurgery (TLM), volumetric modulated arc therapy (VMAT), and MRI-guided stereotactic ablative radiotherapy (MRI-SABR). The primary endpoint is local control (LC). Secondary endpoints include laryngectomy-free survival (LFS), progression-free survival (PFS). overall survival (OS), functional voice, swallowing and breathing outcomes, treatment-related complications, and the evaluation of radiomic and dosiomic biomarkers. Patients will be randomized in a 1:1:1 ratio. Total planned enrollment is 105.",[27,28],"Laryngeal Neoplasm","Glottic Carcinoma",[30,31,32,33,34,35,36],"Early-stage glottic laryngeal cancer","transoral laser microsurgery","VMAT","MRI-SABR","stereotactic radiotherapy","radiomics","dosiomics","RECRUITING","2026-01-29",{"date":40,"type":41},"2026-02-05","ACTUAL",{"date":43,"type":41},"2024-09-01",{"date":45,"type":21},"2034-03",{"name":47,"class":48},"Viktoras Rudzianskas","OTHER",""]